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OBJECTIVES We sought to establish the role of genetic screening for ryanodine receptor type 2 (RyR2)
gene mutations in families with effort-induced polymorphic ventricular arrhythmia (PVA),
syncope and juvenile sudden death.
BACKGROUND The RyR2 mutations have been associated with PVA, syncope and sudden death in response
to physical or emotional stress.
METHODS We studied 81 subjects (39 males and 42 females; mean age 31 20 years) belonging to eight
families with pathogenic RyR2 mutations. All subjects underwent screening for RyR2
mutations, electrocardiography (ECG), 24-h Holter monitoring, signal-averaged electrocar-
diography (SAECG), two-dimensional echocardiography and exercise stress testing. Elec-
trophysiologic (EP) study was performed in nine patients.
RESULTS Six different RyR2 mutations were found in eight families. Forty-three family members
carried the gene mutation. Of these, 28 (65%) showed effort-induced arrhythmic symptoms
or signs and one died suddenly during follow-up. Family history revealed 19 juvenile cases of
sudden death during effort or emotion. In two families sharing the same mutation, no subject
presented with PVA during the stress test; thus, sudden death and syncope were the only
clinical manifestations. The 12-lead ECG was normal in all but two subjects, whereas five
patients showed positive late potentials on the SAECG. In 17 (39.5%) of 43 subjects, the
two-dimensional echocardiogram revealed localized kinetic abnormalities and mild structural
alterations of the right ventricle. The EP study was not able to induce PVA.
CONCLUSIONS The absence of symptoms and PVA on the stress test in more than one-third of carriers of
RyR2 mutations, as well as the lack of PVA inducibility by the EP study, underlies the
importance of genetic screening for the early diagnosis of asymptomatic carriers and
prevention of sudden death. (J Am Coll Cardiol 2002;40:341–9) © 2002 by the American
College of Cardiology Foundation
Effort-induced polymorphic ventricular arrhythmia (PVA)
consists of ventricular arrhythmias with a multifocal pattern
that can progress to polymorphic ventricular tachycardia in
response to vigorous exercise (1). A minor form of arrhyth-
mogenic right ventricular dysplasia (cardiomyopathy) type 2
(ARVD2) characterized by the presence of this type of
effort-induced ventricular arrhythmia was described for the
first time in 1988 (2). The disease locus was mapped to
chromosome 1q42-q43 (3). In the same period, a series of
young patients with stress-induced PVA and a normal QT
interval in the absence of structural abnormalities was also
described (4). Their first symptoms occurred mostly before
the age of 10 years, and these arrhythmias were labeled
“catecholaminergic” because they were supposedly induced
by increased adrenergic stimulation.
Subsequently, linkage to chromosome 1q42-q43 was
confirmed by studying new families with either structurally
normal heart or mild right ventricular (RV) changes (5,6).
The arrhythmias were dangerous, precipitating syncope and
juvenile sudden death in response to physical or emotional
stress. After the exclusion of several candidate genes
mapped to 1q42-q43 (7), three different studies demon-
strated the occurrence of mutations in the human cardiac
ryanodine receptor type 2 (RyR2) gene in affected patients
(7–9). The finding of RyR2 mutations in ARVD2, in both
catecholaminergic ventricular tachycardia and familial poly-
morphic ventricular tachycardia, raised the question of
possible allelism of these diseases. In this investigation, we
assessed the role of genetic screening for RyR2 mutations in
affected families.
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METHODS
Study group. Eight families comprising 81 subjects (39
males and 42 females; mean age 31  20 years) were
identified through index case analysis. The family tree was
reconstructed in each family. The families had been studied
following a case of juvenile sudden death after effort- or
exercise-related syncope or PVA that had occurred in a
family member.
Definition of PVA. The PVAs include isolated premature
ventricular complexes progressing to bigeminy, multifocal
premature ventricular complexes and bursts of polymorphic
ventricular tachycardia. These ventricular arrhythmias are
reproducible with exercise testing and progressively worsen
as the work load increases (1,10).
Study protocol. All subjects underwent 12-lead electrocar-
diography (ECG), signal-averaged electrocardiography
(SAECG), 24-h Holter electrocardiography, exercise stress
testing and two-dimensional echocardiography with Dopp-
ler study. The presence of symptoms such as syncope and
lipothymia and of a family history of syncopal episodes
and/or sudden death was carefully investigated. Invasive
studies were carried out in the setting of syncopal episodes
and/or three or more consecutive premature ventricular
beats (nonsustained ventricular tachycardia).
The electrophysiologic (EP) study included evaluation of
the baseline conduction interval. The protocol for pacing
consisted of the triple extrastimuli technique in two regions
(infundibular and apical) of the RV. In three subjects,
isoproterenol infusion (2 g/min) was also administered.
The methods used for SAECG and two-dimensional
echocardiography have been previously described (11). All
instrumental findings were assessed blindly before the de-
oxyribonucleic acid (DNA) screening results.
The bicycle ergometer test was performed with continu-
ous recording of ECG leads II, aVF and V1 with the
25 W  2 min protocol. In subjects with effort-induced
PVA, beta-blocker therapy was utilized (200 to 400 mg
acebutolol or 100 mg/day atenolol), and the stress test was
repeated every 6 to 12 months to assess the efficacy of
antiarrhythmic therapy. The test was repeated annually in
subjects 25 years of age who had no effort-induced PVA.
Peripheral blood samples were obtained from living
members of each family, with informed consent, and
genomic DNA was extracted according to the salting-out
procedure.
Haplotype analysis. The DNA samples were analyzed by
polymerase chain reaction (PCR) using markers D1S2680,
ACTN2 and D1S184. The PCR reactions were performed
as follows: 100 ng of genomic DNA as a template in 12.5 l
of 1 PCR buffer (16.6 mM ammonium sulfate, 67 mM
Tris hydrochloride [pH 8.3], 0.01% Tween-20, 1.5 mM
magnesium chloride), containing 800 nM of each oligonu-
cleotide, 100 M dinucleotide triphosphate and 0.5 U of
ExperTaq polymerase (ExpertTeam, Venice, Italy). Cycling
conditions (denaturation at 94°C for 1 min, annealing at the
working temperature for 1 min, extension at 72°C for 1
min) were repeated 30 times. After PCR, 2-l aliquots of
the reaction mixture were denatured and separated on 9%
denaturing polyacrylamide gel. The gels were then silver-
stained and dried.
Mutation screening. The PCR reactions were performed
as described previously. All RyR2 primer sequences pro-
duced in our laboratory are available at the Web site:
http://telethon.bio.unipd.it/ARVDnet/molgen_arvd2.html.
Each of the 105 exons was amplified from genomic DNA,
purified (PCR product pre-sequencing kit; USB, Cleveland,
Ohio) and sequenced using BIG DYE dideoxy-terminator
chemistry (Perkin Elmen, Wellesley, Massachusetts) on an
ABI 377 DNA sequencer (PE Applied Biosystems, Foster
City, California). Chromas version 1.5 software (Queens-
land, Australia) and LASERGENE package computer
programs (DNASTAR Inc., Madison, Wisconsin) were
used to edit, assemble and translate the sequences.
Mutation screening in the control group. Once a novel
RyR2 mutation was detected, in order to exclude the
possibility of a nonpathogenic variant, 120 genomic DNAs
(240 chromosomes) from unrelated healthy control subjects
from the Venetian population were analyzed by single-
strand conformation polymorphism or by PCR amplifica-
tion with allele-specific primers designed for the purpose.
The same samples were PCR-amplified using primers for
the wild type. The PCR products were separated on 2%
horizontal agarose gel in 1 tris-acetate EDTA buffer.
Statistical analysis. Statistical analysis was performed us-
ing Statistica version 5.1 (StatSoft, Tulsa, Oklahoma).
Comparisons between patient groups were performed using
the chi-square test or Fisher exact test for categorical
variables. All continuous variables were expressed as the
mean value  SD for each measurement. All tests were
two-tailed, and p  0.05 was considered statistically signif-
icant.
RESULTS
Identification of RyR2 mutations in affected family
members. Screening for RyR2 mutations in families, as
shown in Figure 1, succeeded in detecting two novel
missense mutations (R420W and Y2392C), in addition to
the four previously detected and reported elsewhere (7).
Abbreviations and Acronyms
ARVD2  arrhythmogenic right ventricular dysplasia
(cardiomyopathy) type 2
DNA  deoxyribonucleic acid
ECG  electrocardiogram/electrocardiographic
EP  electrophysiologic
PCR  polymerase chain reaction
PVA  polymorphic ventricular arrhythmia
RV  right ventricle/ventricular
RyR2  ryanodine receptor type 2
SAECG  signal-averaged electrocardiography
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Data are reported in Table 1. In all families, the disease was
inherited as an autosomal-dominant trait. Among 81 sub-
jects who were screened, 43 were found to carry the RyR2
mutation. Twenty-three of 43 carriers have been reported
previously (2–7). All mutations occurred in evolutionarily
conserved regions of the protein, in domains corresponding
to the cytosolic portion of the molecule. As previously
reported (7), the N2386I mutation was detected in two
apparently unrelated families (family nos. 102 and 123)
living in the same small town in the Veneto region. In these
two families, a common haplotype, defined by shared alleles
at markers D1S2680, ACTN2 and D1S184, leads one to
believe that their descendence may have come from a
relatively recent, common ancestor.
Mutation T2504M was found in two unrelated families
(family nos. 115 and 129) who did not share the same
haplotype. Moreover, in affected subjects belonging to
family no. 115, an additional mutation in exon 8 (R176Q)
was detected, as previously reported (7), but has not yet been
detected in the control group.
Novel mutation R420W was detected in two families
(family nos. 125 and 127). Although members of family no.
127 showed no evidence of clinical affection, they share the
same mutation and the same haplotype found in two
affected subjects belonging to an apparently unrelated family
(family no. 125), thus supporting the presence of a relatively
recent, common ancestor. It should be noted that three
members of family no. 127 had juvenile sudden death.
Unfortunately, the DNA was not available, nor could their
haplotype be indirectly obtained for the study. Affected
members of family no. 122 inherited the mutation L433P,
although the novel Y2392C mutation was detected in family
no. 126.
In each family, the detected RyR2 mutations were shown
to be invariably transmitted from patient to patient along
generations and were never detected in the control group.
The penetrance of RyR2 pathogenic mutations, estimated
on the basis of clinical and instrumental findings, was
significantly different among families (Table 1).
Asymptomatic carriers of pathogenic RyR2 mutations.
The proportion of asymptomatic subjects among carriers of
the RyR2 mutation was estimated on the basis of results
obtained from clinical and instrumental investigations (Ta-
bles 2 and 3). Among the 43 subjects carrying the RyR2
mutation, 15 (35%) were fully asymptomatic (5 males and
10 females; mean age at the last visit: 40  29 years).
Effort-induced PVA and syncope. Twenty-eight (65%) of
43 subjects (13 males and 15 females; mean age 28  12
years [range 11 to 51 years]) presented with effort-induced
arrhythmic symptoms or signs (Figs. 2 and 3): effort PVA in
26 subjects and isolated syncopal episodes in 2 subjects. In
9 subjects (6 males and 3 females; mean age 22  11 years
[range 11 to 44 years]), there were no arrhythmic symptoms
during the first visit, but they appeared during follow-up.
One of them died suddenly during follow-up at the age of
20 years, without treatment.
No patient had documented PVA or syncopal episodes
before the age of 11 years. When comparing arrhythmic
with nonarrhythmic subjects carrying the RyR2 mutation,
no statistically significant difference was found regarding
gender and age (13 males and 15 females vs. 10 males and
5 females and 28  12 years vs. 39  29 years, respectively;
p  NS). Eight subjects experienced syncopal episodes (3
males and 5 females; mean age 14  2 years) before the
diagnosis and while they were not protected by antiarrhyth-
mic therapy. None of the subjects without the RyR2
mutation showed PVA during the stress test. Among the 26
subjects who had PVA during exercise, 15 presented with
polymorphic ventricular complexes, either isolated or in
couplets, whereas in 10 subjects, PVA progressed to non-
sustained ventricular tachycardia. In one subject, sustained
ventricular tachycardia was induced (Table 2). In all but
three cases, the arrhythmias originated from both the left
and RVs. The PVAs were related to a heart rate increase
during effort, and each subject seemed to have a reproduc-
ible threshold of heart rate at which the PVAs appeared.
The average sinus rate at the onset of arrhythmias was
127  14 beats/min, and in all subjects, PVA disappeared
during the first minute of recovery.
Additional clinical findings. In all 43 RyR2 mutation
carriers (100%), the 12-lead ECG showed normal sinus
rhythm and normal atrioventricular conduction. Mild ST-
segment elevation (1 mm) in the right precordial leads was
present in two subjects (5%), and the QT interval was
Table 1. RyR2 Mutations Detected in Affected Families
Amino Acid
Change
Nucleotide
Change
Exon
No. Consequence Protein Domain
Family
No.
Estimated
Penetrance
N2386I 7157A3T 47 MM FKBP12.6 domain 102 94%
N2386I 7157A3T 47 MM FKBP12.6 domain 123
R176Q 527G3A 8 MM Cytosolic portion 115 100%
T2504M 7511C3T 49 MM FKBP12.6 domain 115 50%*
T2504M 7511C3T 49 MM FKBP12.6 domain 129
R420W 1258C3T 14 MM Cytosolic portion 125 25%
R420W 1258C3T 14 MM Cytosolic portion 127
L433P 1298T3C 15 MM Cytosolic portion 122 80%
Y2392C 7175A3G 47 MM FKBP12.6 domain 126 50%
*In family no. 115, the estimated penetrance for mutation T2504M was 100%; however, it was not possible to determine the
influence of the additional sequence variation R176Q on the clinical phenotype.
MM  missense mutation; RyR2  ryanodine receptor type 2.
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Figure 1. Pedigrees of eight families. Family nos. 102, 123, 115 and 122 have been already reported (7). Corresponding ryanodine receptor type 2 (RyR2)
mutations identified by deoxyribonucleic acid (DNA) sequence analysis are reported on the right side. (A) The DNA sequencing of subjects from family nos. 125
and 127 revealed a C3T transition, which changes codon 420 from CGG to TGG, resulting in Arg3Trp substitution. In family no. 126, DNA sequencing
of RyR2 exon 47 in all family members revealed an A3G transition, leading to Tyr2392Cys substitution. The DNA sequencing of RyR2 exon 49 in subjects
belonging to family no. 129 showed a C3T transition, resulting in Thr3Met substitution.
Figure 1. Continued from previous page. (B) The DNA sequencing of subjects from family nos. 102 and 123 revealed an A3T transversion, which changes
codon 2386 from AAC to ATC, resulting in Asn3 Ile substitution. In family no. 115, DNA sequencing of RyR2 exons 49 and 8 in all family members
revealed two transitions (C3T in exon 49 and G3A in exon 8), leading to Thr2504Met and Arg176Gln substitutions. The DNA sequencing of RyR2
exon 15 in subjects belonging to family no. 122 showed a T3C transition, resulting in Leu3Pro substitution.
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normal in all. On the SAECG, late potentials were recorded
in five subjects (12%). The Holter ECG revealed sporadic
monomorphic ventricular complexes (30/h) in four sub-
jects (9%). In 17 (39.5%) of 43 gene mutation carriers
belonging to four families, the two-dimensional echocar-
diogram revealed kinetic alterations of the RV (Table 3).
Mild structural abnormalities (trabecular thickening and a
highly reflecting moderator band), in the setting of a normal
or slightly enlarged RV, were also found in 26 affected
subjects (60%). Left ventricular volume and kinetics were
normal in all subjects. Right and left ventricular angiogra-
phy with coronary arteriography performed in seven affected
subjects confirmed the two-dimensional echocardiographic
findings. In nine subjects who underwent EP study, ven-
tricular arrhythmias were not induced, even during isopro-
terenol infusion. Structural abnormalities of the RV have
never been detected in family members who did not carry
the gene mutation.
Follow-up. Beta-blocker therapy was administered in the
26 patients with effort-induced PVA. In addition, a
cardioverter-defibrillator was implanted in a patient with a
previous syncopal episode and a family history of juvenile
sudden death (family no. 125). The stress test, which was
repeated periodically, showed the disappearance of effort-
induced PVA in 17 subjects (65%) who had beta-blocker
therapy. In the remaining subjects, arrhythmias were trig-
gered at a higher level of load; thus, the antiarrhythmic drug
dosage was increased. Moreover, patients were strongly
advised to avoid strenuous physical activity. During
follow-up (mean 6.5 years [range 6 months to 14 years]), no
patient on antiarrhythmic therapy had syncopal episodes or
died suddenly.
Family history of juvenile sudden death. Families pedi-
gree showed that 19 patients (12 males and 7 females; mean
age 20  6 years) died suddenly during effort. One of them,
who was considered unaffected, died during follow-up.
Subsequent genetic study of blood samples obtained during
life detected the presence of the RyR2 mutation running in
the family (family no. 125). None of the subjects who had
sudden death was receiving anti-arrhythmic therapy. FourTa
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Table 3. Twelve-Lead ECG, SAECG and Two-Dimensional
Echocardiographic Findings in RyR2 Mutation Carriers
Family
No.
Subjects With
RYR2
Mutations
Abnormal
12-Lead ECG
Positive
SAECG
Right Ventricular
Kinetic
Alterations
102 14 0 3 (21) 13 (93)
123 2 0 0 0
115 3 0 0 2 (66)
129 7 1 (14) 1 (14) 0
125 6 0 0 1 (17)
127 2 1 (50) 1 (50) 0
122 5 0 0 1 (20)
126 4 0 0 0
Total 43 2 (5%) 5 (12%) 17 (39.5%)
Data are presented as the number (%) of subjects.
ECG  electrocardiography; RyR2  ryanodine receptor type 2; SAECG 
signal-averaged electrocardiography.
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subjects (21%) had syncopal episodes, whereas in the re-
maining 15, sudden death appeared to be the first clinical
manifestation.
Autopsy findings. Postmortem examination was per-
formed in seven subjects, and the findings were a structur-
ally normal heart in three (family nos. 123, 125 and 126),
mild fatty infiltration of the RV apex in three (family nos.
125 [n  2] and 102 [n  1]) and a typical form of
fibro-fatty arrhythmogenic RV cardiomyopathy in one
(family no. 115).
DISCUSSION
The RyR2 mutations are known to be specifically linked to
effort-induced PVA, syncope and sudden death. This study
reports the genetic, clinical and instrumental findings of a
group of patients with the RyR2 mutation and PVAs. In
contrast to a previous report (7) that specifically dealt with
the basic genetic aspects of the disease, here we examined, in
detail, the clinical phenotype and demonstrated the role of
genetic screening for the presymptomatic diagnosis of sub-
jects carrying the RyR2 mutation, as well as the efficacy of
antiarrhythmic therapy. Moreover, a high variability in
phenotypic expression among affected subjects belonging to
the same family or to unrelated families was demonstrated.
Phenotypic expression. Recently it has been shown that
mutations in the RyR2 gene are involved in the onset of
PVA during effort, either in patients with a normal heart or
in those with ARVD2 (7–9). Because the incidence of
juvenile sudden death is very high and beta-blocker therapy
seems to be effective, the early identification of subjects
carrying these mutations, with prompt treatment, is crucial.
In the clinical setting, variability of a single mutation
among siblings and offspring of an affected family suggests
that additional factors play a role in the phenotypic expres-
sion of RyR2 mutations. The function of RyR2 can be
modulated by many substances, such as endogenous/
physiologic chemicals (e.g., calcium ions, lactate, palmitoyl
carnitine) and exogenous/pharmacologic modulators (e.g.,
caffeine, sulmazole, suramin, volatile anesthetics, immuno-
suppressant macrolides, heparin) (12).
The finding of RyR2 mutations in ARVD2, cat-
echolaminergic ventricular tachycardia and familial poly-
morphic ventricular tachycardia raised the question of pos-
sible allelism of these diseases, as occurring in malignant
hyperthermia and central core disease, in which a similar
genetic defect leads to subtle phenotypic variation (7–9). In
particular, the clinical picture of Finnish patients with
familial polymorphic ventricular tachycardia is similar to
Figure 2. Electrocardiographic monitoring during the stress test (family no. 126, subject II-4). (Left panel, limb leads) Appearance of monomorphic
ventricular complexes that create a bigeminy. As the effort increases, premature ventricular complexes become multifocal and repetitive. (Right panel,
precordial leads)
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that of our patients with ARVD2, except for the RV
abnormalities that we observed on the two-dimensional
echocardiogram or at postmortem analysis in more than
one-third of cases. Our data support the hypothesis that the
imbalance of intracellular calcium homeostasis due to the
RyR2 mutation could trigger cell death, either necrosis or
apoptosis (13–19), thus leading, with time, to ARVD2 in a
subgroup of patients. The unusual ECG features of poly-
morphic ventricular tachycardia, a finding that might argue
against underlying arrhythmogenic RV cardiomyopathy,
was already described in the early 1980s when Morady et al.
(20), reporting on a subject with this ECG pattern, argued
that some patients with arrhythmogenic RV cardiomyopa-
thy may have ventricular arrhythmias due to catecholamine-
induced automaticity rather than reentry, thus explaining
why ventricular tachycardia may not have the typical left
bundle branch block configuration.
Screening for mutations of the RyR2 gene. The cardiac
ryanodine receptor plays a crucial role in excitation-
contraction coupling by releasing Ca2 ions from the
sarcoplasmic reticulum after stimulation by calcium ions
entering through the dihydropyridine receptor (14–16). All
the missense mutations detected in the RyR2 gene reported
herein occurred in the cytosolic portion of the molecule, in
domains of the protein that are crucial for the regulation of
the calcium channel (17), and resulted in substitutions of
amino acids highly conserved through evolution. The RyR2
mutations resulted in clustering in two regions, whereas
mutations causing malignant hyperthermia or central core
disease were also clustered in the corresponding skeletal
muscle ryanodine receptor gene (RyR1) (18).
In the families reported in this study, six different RyR2
mutations have been identified. None of them was found in
the control group, supporting the hypothesis that these
genetic variants are pathogenic. As family no. 127 includes
two asymptomatic individuals in whom this mutation has
been found and three sudden death cases that were not
genetically examined, the presence of a rare amino acid
polymorphism cannot be excluded. However, this family
shares the same mutation as family no. 125, in which
symptomatic carriers were present and in which a common
at-risk haplotype was found, thus suggesting the existence
of a relatively recent, common ancestor. Further functional
studies will be necessary to determine whether this amino-
acid substitution is indeed a disease-causing mutation. In
contrast, the RyR2 mutation T2504M occurred in two
independent families showing different at-risk haplotypes.
In this case, the possibility of a common, remote ancestor
might be considered, but the possibility of two independent
mutations affecting the same nucleotide cannot be ruled out.
Clinical findings. More than one-third of carriers of the
RyR2 mutation did not show effort-induced PVA, syncope
or juvenile sudden death. Arrhythmias were variable, rang-
ing from isolated premature ventricular beats to sustained
ventricular tachycardia. Some subjects were fully asymptom-
atic, whereas others showed late-onset arrhythmias in their
adulthood. In two families (family nos. 125 and 127)
sharing the same mutation (R420W) and a common ances-
tor, syncope and sudden death were the only clinical
manifestations, and the stress test was unable to induce
PVA. This suggests that the clinical spectrum of RyR2
mutations should include a totally asymptomatic behavior,
even after stress testing.
Because routine cardiovascular diagnostic testing mostly
showed normal asymptomatic carriers, a negative test in an
Figure 3. Distribution of patients with effort-induced polymorphic ventricular arrhythmias and/or syncope in relation to age.
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apparently healthy subject cannot exclude the risk of sudden
death, as demonstrated by the fatal outcome of one patient
previously assumed to be unaffected.
Based on the limited number of subjects sharing the same
mutation, it is still not feasible to determine the predictive
value of the specific mutations. However, mutation N2386I
detected in family nos. 102 and 123 (total of 16 subjects
carrying the mutation) seems to be associated with a high
inducibility of PVA during stress testing. The penetrance of
pathogenic mutations was significantly different among
families in our series. At present, it is impossible to define
whether this corresponds to the actual biologic properties of
the different mutations, or whether it simply depends on the
very small sample size. Nevertheless, statistical analysis
revealed that the different penetrance of arrhythmic symp-
toms or signs depends neither on age nor gender.
Juvenile sudden death occurred frequently in affected
families. A postmortem report was obtained only in a few
cases, and tissues specimens were unavailable for genetic
study, so it was impossible to directly link sudden death to
RyR2 mutations. However, the presence of such a high
incidence of juvenile sudden death in families with RyR2
mutations suggests that gene mutation carriers are at risk of
sudden death.
As far as the pathophysiology of PVA in patients carrying
RyR2 mutations, an increased calcium leak from the sarco-
plasmic reticulum, due to RyR2 channel “gain of function,”
has been postulated. The presence of a hyperactive RyR2
gene would provoke the onset of delayed afterdepolariza-
tions that could trigger ventricular arrhythmias (21,22).
Conclusions. Screening for RyR2 mutations in families
with effort-induced PVA and sudden death revealed a high
proportion of asymptomatic carriers. The risk stratification
of sudden death in asymptomatic carriers is a challenge,
because the first manifestation of the disease may be fatal.
The unforeseeable risk of juvenile sudden death and the
proven efficacy of beta-blocker therapy underscore the role
of genetic screening for early diagnosis and preventive
strategies.
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